New Intravesical Delivery Systems and TAR-200 in NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems and agents under investigation, and provide information about TAR-200, a targeted release system utilizing continuous intravesical release of gemcitabine, including how TAR-200 is installed within the bladder.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

Now Viewing

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

Video content above is prompted by the following:

Please review different treatment delivery options available for management of NMIBC.
It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for treatment of NMIBC.
To start with, please share information about TAR-200, a targeted release system that utilizes continuous intravesical release of gemcitabine.
Describe how TAR-200 is installed within the bladder.